Home › Legal Status › Illinois
Illinois
Psilocybin legal status, legislation & access — 2025
State-level frameworks do not change federal controlled-substance status.
Status depends on the activity: possession, supervised administration, sale, transport, cultivation, research, and service provision may be treated differently.
What local context does not answer
Local context can explain policy history, state rules, city ordinances, public-health resources, and community support. It cannot determine whether a substance is safe, effective, lawful for a specific person, available through a specific channel, or appropriate for any individual.
Enforcement context
Psilocybin remains a Schedule I controlled substance under the Illinois Controlled Substances Act. No statewide decriminalisation or therapeutic access legislation has passed. Proposals including SB 2582 (2023) sought to create a therapeutic framework but did not advance. Chicago hosts significant psychedelic research infrastructure through Northwestern University's Feinberg School of Medicine and the University of Chicago, positioning Illinois as a likely early-adopter state once federal rescheduling progresses. No Illinois municipality has enacted a local decriminalisation ordinance as of 2025.
Cities in Illinois
Frequently asked questions
Is psilocybin legal in Illinois?
No. Psilocybin is a Schedule I controlled substance in Illinois. Pending legislation including SB 2582 has proposed therapeutic access frameworks, but none have passed as of 2025.
Has any Illinois city decriminalised psilocybin?
No Illinois city has formally decriminalised psilocybin as of 2025. Unlike cities in Massachusetts or Michigan, no Illinois municipality has passed a local decriminalisation ordinance for entheogenic substances.
What psilocybin research is happening in Illinois?
Northwestern University's Feinberg School of Medicine and the University of Chicago are leading Midwest psychedelic research institutions, with ongoing studies into psilocybin-assisted therapy for depression, addiction, and end-of-life anxiety — establishing a substantial research base ahead of potential legislative change.